Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study

類似資料

• Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS
  著者:: Cohen, Jeffrey A., 等
  出版事項: (2013)
• Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
  著者:: Gold, Ralf, 等
  出版事項: (2013)
• Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
  著者:: Kappos, Ludwig, 等
  出版事項: (2015)
• Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
  著者:: Kappos, Ludwig, 等
  出版事項: (2015)
• Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
  著者:: Kappos, Ludwig, 等
  出版事項: (2015)